Skip to main content
Top
Published in: Journal of Clinical Immunology 5/1999

01-09-1999

Long-Term Follow-Up of the Changes in Circulating Cytokines, Soluble Cytokine Receptors, and White Blood Cell Subset Counts in Patients with Rheumatoid Arthritis (RA) After Monoclonal Anti-TNFα Antibody Therapy

Authors: Shiro Ohshima, Yukihiko Saeki, Toru Mima, Mitsuko Sasai, Katsuhiro Nishioka, Hiroshi Ishida, Masatoshi Shimizu, Masaki Suemura, Richard McCloskey, Tadamitsu Kishimoto

Published in: Journal of Clinical Immunology | Issue 5/1999

Login to get access
Metadata
Title
Long-Term Follow-Up of the Changes in Circulating Cytokines, Soluble Cytokine Receptors, and White Blood Cell Subset Counts in Patients with Rheumatoid Arthritis (RA) After Monoclonal Anti-TNFα Antibody Therapy
Authors
Shiro Ohshima
Yukihiko Saeki
Toru Mima
Mitsuko Sasai
Katsuhiro Nishioka
Hiroshi Ishida
Masatoshi Shimizu
Masaki Suemura
Richard McCloskey
Tadamitsu Kishimoto
Publication date
01-09-1999
Publisher
Kluwer Academic Publishers-Plenum Publishers
Published in
Journal of Clinical Immunology / Issue 5/1999
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1023/A:1020543625282

Other articles of this Issue 5/1999

Journal of Clinical Immunology 5/1999 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine